Murat Araz

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Venues

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

European journal of clinical pharmacology

Current medical research and opinion

Necmettin Erbakan University Meram Faculty of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Necmettin Erbakan University Meram Faculty of Medicine Oct 05 2018

Turkey

Assistant Professor :: Medical Oncology

Publications

Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mustafa Yıldırım
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. European journal of clinical pharmacology 80 (6) (2024)
Oğuzhan Yıldız, Ali Fuat Gürbüz, Melek Karakurt Eryilmaz, Murat Araz, Talat Aykut, Özlem Şahin, Naciye Hilal Büyükboyacı, Zeliha Çelik, Mustafa Yıldırım
Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Kadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek, Nilgun Yıldırım, Fatih Gürler, Ozan Yazıcı, Ahmet Özet, Öznur Bal, Murat Araz, Mustafa Yıldırım, Nuriye Ozdemir
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study. Current medical research and opinion (2024)
Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mustafa Yıldırım
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. European journal of clinical pharmacology (2024)
Ali Fuat Gürbüz, Melek Karakurt Eryilmaz, Oğuzhan Yıldız, Bahattin Engin Kaya, Murat Araz, Mustafa Yıldırım
Lorlatinib experience in a patient with ALK + non-small cell lung cancer on hemodialysis: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Kadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek, Nilgun Yıldırım, Fatih Gürler, Ozan Yazıcı, Ahmet Özet, Öznur Bal, Murat Araz, Mustafa Yıldırım, Nuriye Ozdemir
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study. Current medical research and opinion (2024)
Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mustafa Yıldırım
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. European journal of clinical pharmacology 80 (6) (2024)
Murat Araz, Ismail Beypinar, Fatih Inci, Lokman Koral, Mehmet Zahid Koçak, Mustafa Korkmaz, Aykut Demirkıran, Melek Karakurt Eryilmaz, Mustafa Yıldırım
Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Kadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek, Nilgun Yıldırım, Fatih Gürler, Ozan Yazıcı, Ahmet Özet, Öznur Bal, Murat Araz, Mustafa Yıldırım, Nuriye Ozdemir
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study. Current medical research and opinion 40 (7) (2024)
Mustafa Korkmaz, Melek Karakurt Eryilmaz, Muhammed Muhiddin Er, Mehmet Zahid Koçak, Aykut Demirkıran, Mustafa Karaağaç, Murat Araz, Mustafa Yıldırım, Zahid Mehmet Koçak
Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy? Journal of gastrointestinal cancer (2023)
Tuba Karaçelik, Buğra Kaya, Mustafa Korkmaz, Mustafa Karaağaç, Murat Araz, Melek Karakurt Eryilmaz, Hakan Şat Bozcuk, Mustafa Yıldırım
Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer. Journal of gastrointestinal cancer (2022)
Murat Araz, Melek Karakurt Eryilmaz
Immunotherapy era in the treatment of small cell lung cancer. Medical oncology (Northwood, London, England) 38 (7) (2021)
Muzaffer Uğraklı, Murat Araz, Aykut Demirkıran, Ahmet Faruk Çelik, Melek Karakurt Eryilmaz, Mustafa Karaağaç, Mustafa Yıldırım
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (3) (2021)
Tuba Karpuz, Murat Araz, Levent Korkmaz, Ibrahim Kılınc, Sidika Findik, Mustafa Karaagaç, Melek Karakurt Eryilmaz, Mehmet Artac
The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer. Journal of gastrointestinal cancer 51 (2) (2021)
Ismail Beypinar, Hacer Demir, Murat Araz, Meltem Baykara, Nuri Faruk Aykan
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. Journal of gastrointestinal cancer (2020)
Murat Araz, Mustafa Karaagac, Levent Korkmaz, Lokman Koral, Fatih Inci, Ismail Beypinar, Mukremin Uysal, Mehmet Artac
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. Cancer chemotherapy and pharmacology 83 (6) (2019)

Murat Araz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Murat Araz